Rigel Pharmaceuticals | L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Agenus USD -274.14M 80.46M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Anika Therapeutics USD -3.87M 32.43M 2025-03
Arrowhead Research USD 28.27M 7.85M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Celldex Therapeutics USD -67.04M 10.44M 2025-09
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -4.85M 4.39M 2024-09
Intrexon USD -60.48M 27.09M 2024-06
Ionis Pharmaceuticals USD -129M 253M 2025-09
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
MacroGenics USD 16.82M 52.97M 2025-09
Neurocrine Biosciences USD 291.8M 132.3M 2025-09
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Rigel Pharmaceuticals USD -1.03M 7.22M 2024-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Ultragenyx Pharmaceutical USD -179.54M 65.54M 2025-09
Veracyte USD 18.89M 17.64M 2025-09


Rigel Pharmaceuticals L'Utile Ante Imposte - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.